Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

6 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

6(66.7%)

Phase 2

2(22.2%)

Phase 1

1(11.1%)

9Total

Phase 3(6)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04565015Phase 3Active Not Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Role: collaborator

NCT02887859Phase 2Completed

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

Role: collaborator

NCT03005418Phase 2Active Not Recruiting

Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma

Role: collaborator

NCT02783482Phase 3Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Role: collaborator

NCT02269163Phase 3Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Role: collaborator

NCT01967043Phase 1Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

Role: collaborator

NCT01619046Phase 3Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Role: collaborator

NCT01406470Phase 3Completed

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Role: collaborator

NCT02027779Phase 3Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Role: collaborator

All 9 trials loaded